Corcept Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue was $340.5 million, up 33% from the second quarter and 64% from the prior year period.
- Corollary and authorized generic revenue was $249.1 million, and The fairly revenue was $91.4 million.
- Net income was $126.8 million, compared with $43 million in the second quarter and $19.7 million in the prior year period.
- Cash and investments as September 30 were $662 million, an increase of $118 million in the quarter; the company acquired 44 million dollars of its common stock in the third quarter.
- The endocrinology division delivered another quarter of record revenue, with management citing increased prescribing and more patients benefiting from its medicines.
- Le Fiori revenue was $91.4 million, a 92% increase; more than 1,700 physicians had prescribed it to more than 2,300 patients since April 1st launch.
- Management reported strong demand and increasing repeat prescribing for Le Fiori, as well as growing use earlier in treatment for platelet-resistant ovarian cancer.
- In Arm A of the Bella phase II trial, 95 patients receiving oral equivalent plus Napaclitaxel and Bevacizumab had median progression-free survival of 7.2 months, objective response rate of 59%, and overall survival of 88% at six months; median overall survival was not yet reached at the time of the primary analysis.
- In Monarch, patients receiving 200 milligrams of Miraquivalent twice a week had a larger reduction in liver fat than patients receiving 100 milligrams twice a week; fibrosis improvement was 19.2% in patients receiving 100 milligrams twice a week over 48 weeks.
- Miraquivalent was very well tolerated in both Monarch cohorts, with adverse-event rates virtually indistinguishable between the Miraquivalent and placebo arms.
- Management said treatment with a cortisol modulator in the phase II DASLS trial resulted in a profound reduction in early mortality in patients with ALS.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Please be advised that today's conference is being recorded. It is now my pleasure to introduce CFO, Atabak Mokari.
Hello, everyone. Good afternoon and thank you for joining us. Today, we issued a press release announcing our financial results for the third quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements express or imply. The risks and uncertainties that may affect our forward-looking statements are described in our annual report on Form 10-K and our quarterly reports on Form 10-Q, which are available at the SEC's website.
Please refer to those documents for more information. We disclaim any intention or duty to update forward-looking statements. Our revenue in the third quarter of 2026 was $340.5 million, a 33% increase from the second quarter and a 64% increase compared to the prior year period. Korlym and authorized generic revenue was $249.1 million. Lifyorli revenue was $91.4 million. We expect our growth to continue and are reiterating our 2026 revenue guidance of $1.1 billion-$1.2 billion. Net income was $126.8 million in the third quarter of 2026, compared to $43 million in the second quarter and $19.7 million in the prior year period. Our cash and investments at September 30 were $662 million, an increase of $118 million in the quarter.
We acquired $44 million of our common stock in the third quarter pursuant to our stock repurchase program, the exercise of Corcept stock options, and the vesting of restricted stock grants. I will now introduce Justin Gunn, President of our endocrinology division. Justin assumed this role at the beginning of October. Prior to that, he was the Vice President of Sales for our oncology division. Justin has more than two decades experience as a biopharma executive in a variety of commercial roles, including the successful launch of nine products in multiple therapeutic areas.
Justin. Thank you, Atabak. It's an exciting time to step into this new role.
Over the past month, I've gotten to know many of my new colleagues in Corcept's outstanding endocrinology team. The endocrinology division delivered another quarter of record revenue, an accomplishment that I'm pleased to announce but take no credit for. Its skilled professionals have also helped create the conditions that will fuel future growth. More physicians are prescribing our medicines, and more patients are benefiting from them from ever before. At the same time, realizing the full potential of our business will take, as it always has, hard work, creativity, and perseverance. I look forward to helping in that, lead that effort. Hypercortisolism remains underdiagnosed and undertreated. Our CATALYST and MOMENTUM studies prove that hypercortisolism is far more prevalent than previously understood, and these landmark findings are poised to change diagnostic and treatment paradigms.
Of course, it takes time to incorporate scientific advances into new standards of care. Articles in leading journals, such as publications in Diabetes Care describing our CATALYST results, are invaluable first steps. But in my experience, the support of medical societies is required to really raise awareness among these busy physicians. We were gratified that the American Diabetes Association cited our CATALYST findings in its Consensus 2026 report in the management of type 2 diabetes released in October. The report recommends screening for hypercortisolism in patients whose blood sugar remains high despite treatment with multiple glucose-lowering medications, and states that the treatment of mifepristone reduced hemoglobin A1C substantially in these patients. The Consensus report follows the American Association of Clinical Endocrinology's reference to CATALYST findings in its guidance for the management of diabetes issued in March of this year.
As the ADA and the AACE recommendations become incorporated into medical practice, more patients are going to be screened, diagnosed, and treated for hypercortisolism. As a result, we expect our current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of this decade. The availability of relacorilant driving faster growth to between $3 billion and $5 billion in 2030. I'll now turn the call over to Roberto Vieira, President of our oncology division.
Roberto. Thanks, Justin. Lifyorli delivered exceptional growth in its second quarter on the market.
Revenue grew to $91.4 million, a 92% increase. Demand for Lifyorli remains strong, reflecting the significant unmet need in platinum-resistant ovarian cancer and growing physician adoption. The reasons for Lifyorli's rapid uptake are straightforward. It provides the compelling overall survival benefits driven by its unique mechanism of action, which both enhances the immune system's ability to kill tumor cells and increases those cells' sensitivity to chemotherapy. It is well tolerated, with a very manageable safety profile. Screening for a biomarker is not required. Virtually all tumor cells in ovarian cancer express the glucocorticoid receptor. Finally, Lifyorli is an oral medication, which makes it easy to administer. More than 1,700 physicians have prescribed Lifyorli to more than 2,300 patients since April 1st launch.
That number continues to grow across specialties and treatment settings, including gynecologic medical and hematologic oncologists at academic and non-teaching hospitals, as well as community oncology clinics across the country. At the same time, repeat prescribing continues to increase, reflecting prescribers' growing familiarity with and confidence in Lifyorli. We expect this trend to continue. Another important trend we are seeing is the use of Lifyorli in earlier lines of therapy. Lifyorli is approved to treat patients in the second to fourth lines of treatment for platinum-resistant ovarian cancer. As it is typical of newly approved anti-cancer agents, many of the first patients to be prescribed Lifyorli had already received multiple lines of treatment.
But the data show that Lifyorli is particularly well-suited to help patients at the earliest end of that range, so that Lifyorli's ability to enhance their immune system response to cancer, a benefit which persists even after Lifyorli is discontinued, can have its optimal long-term effect. Our BELLA trial results make the rationale for using Lifyorli earlier in treatment even stronger. Bevacizumab is a standard of care treatment for patients with earlier stage of ovarian cancer. In BELLA Arm A, Lifyorli was added to treatment with nab-paclitaxel and bevacizumab. Patients demonstrated substantial benefits in progression-free survival, objective response rate, and overall survival. The patients with the best response were those earliest in their course of treatment in the platinum-resistant setting. Physicians will consider this important finding as they sequence the treatments their patients receive.
The increasing number and proportion of patients who receive Lifyorli earlier in their treatment is yet another factor driving the growth of our business. Lifyorli's launch has exceeded expectations. We believe Lifyorli is on its way to becoming the market share leader in platinum-resistant ovarian cancer. We believe Lifyorli will generate more than $1 billion in annual revenue. I now turn the call over to Joe Belanoff, our Chief Executive Officer.
Joe. Thank you, Roberto, and thank you everyone for joining us.
Since our founding, Corcept has worked to discover and develop molecules that harness glucocorticoid receptor, GR antagonism, to treat serious diseases. The potential is enormous, and we have made important progress. It is now established that hypercortisolism is much more prevalent than previously believed, and that modulating cortisol's activity can help many patients. Lifyorli's emerging position as a new standard for platinum-resistant ovarian cancer highlights the potential of GR antagonism to treat many types of solid tumors, and our plans go well beyond Cushing's syndrome and oncology. We are heartened by the growing recognition of hypercortisolism within the medical community.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
